drugset / Trial / NCT06210815
A Study of HLX42 in Advanced/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.
Timeline
- Start
- 2024-03-14
- Primary completion
- 2026-09-02
- Completion
- 2027-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX42 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | HLX42 | Monoclonal antibody | 2.5 mg/kg | Intravenous |